The global focus on gene and cell therapies has grown exponentially in recent years as more development programs have advanced to later stages or even approval. In this article published in Life Science Leader, the authors discuss the challenges for gene and cell therapy research and how new approaches to innovation and financing, such as platform diversification and partnering with academia, could help support development of cell and gene therapies. To access the article, click here.
The authors wish to acknowledge the contributions of Pascale Diesel, Stephanie Donahue, and Michael Krepps to this article.
From spreadsheet to strategy: How leading pharma companies transform annual brand planning into competitive advantage
Insight as your ABP backbone Annual Brand Planning (ABP) should not feel like a reinvention exercise every year, particularly for established brands. Instead,...